<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02515656</url>
  </required_header>
  <id_info>
    <org_study_id>PGX 401-11</org_study_id>
    <secondary_id>2014-001759-22</secondary_id>
    <nct_id>NCT02515656</nct_id>
  </id_info>
  <brief_title>Assessment of the Efficacy of POLYGYNAX® in the Empirical Treatment of Infectious Vaginitis</brief_title>
  <acronym>PRISM</acronym>
  <official_title>Assessment of the Efficacy of POLYGYNAX® in the Empirical Treatment of Infectious Vaginitis International, Multicentre, Randomised, Double-blind, Parallel Group Study, Comparative Versus Miconazole</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratoire Innotech International</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>International Clinical Trials Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Venn Life Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Laboratoire Innotech International</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      POLYGYNAX® is a broad spectrum combination of nystatin, neomycin and polymixin B indicated
      for the local treatment of vaginitis due to sensitive germs and treatment of non specific
      vaginitis of adults. POLYGYNAX® has been marketed in France since 1969.

      Nevertheless, despite the well established use of POLYGYNAX®, there is no clinical study
      supporting the interest of the combination of antifungal and antibiotics agents versus
      antifungal agent alone.

      The aim of this project is to demonstrate that POLYGYNAX® is more effective than miconazole
      in the treatment of women experiencing symptoms of infectious vaginitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Treatment Efficacy Assessed by the Investigator After Thorough Gynaecological Examination and Patient's Interview at End of Treatment Visit</measure>
    <time_frame>15 days after first treatment administration</time_frame>
    <description>Success is defined by resolution (return to patient's usual gynaecological conditions, i.e. before the episode which warranted inclusion in the study) OR substantial improvement of clinical signs of infectious vaginitis (i.e. abnormal vaginal discharge), and/or vaginal symptoms (vaginal burning and/or vaginal pain, and/or vaginal irritation).
Failure is defined by persistence or worsening of symptoms and clinical signs or requirement of an alternative or specific treatment.
Not considered as &quot;Treatment Failure&quot;:
The need to initiate a specific treatment because of a Sexually Transmitted Infection (STI) (trichomoniasis; gonococcal and chlamydial infections) detected from the vaginal sample at Visit 1 / D1.
Patients presenting with only vulvar complaints not considered as related to infectious vaginitis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Vaginal Discharge and in Each Associated Vaginal Clinical Symptoms Reported by the Patient in the Diary</measure>
    <time_frame>during 14 days after first treatment intake</time_frame>
    <description>This outcome was evaluated using a Visual Analogue Scale (VAS) completed by the patient.
The scale measured the level of each vaginal symptom experienced during the day (vaginal discharge, vaginal burning, vaginal pain and vaginal irritation).
Scale ranges = 0 to 100 0=none symptom 100=maximum intensity of symptom Time points used in the calculation= D1 to D14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Change in Vaginal Discharge Assessed by the Investigator</measure>
    <time_frame>15 days after first treatment administration</time_frame>
    <description>The vaginal discharge is assessed by the investigator by using a score:
0=absent
mild: insufficient for speculum collection
moderate: sufficient for speculum collection
abundant: visible at the introitus even before speculum introduction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Treatment Efficacy (Success/Failure) Assessed by the Investigator After Thorough Gynaecological Examination and Patient's Interview at End of Study Visit</measure>
    <time_frame>22 days after first treatment administration</time_frame>
    <description>Success and Failure (same definition as the primary outcome measure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator's Global Satisfaction</measure>
    <time_frame>15 days after first administration</time_frame>
    <description>The investigator filled the satisfaction questionnaire during the end of treatment visit.
Six ratings are available: Very Bad, Bad, Somewhat Bad, Somewhat Good, Good and Very Good.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Global Satisfaction</measure>
    <time_frame>15 days after first administration</time_frame>
    <description>The patient filled the satisfaction questionnaire on her patient's diary at home the eve of the End of Treatment Visit.
Six ratings are available: Very Bad, Bad, Somewhat Bad, Somewhat Good, Good and Very Good.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">661</enrollment>
  <condition>Vaginitis</condition>
  <arm_group>
    <arm_group_label>POLYGYNAX®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Name : POLYGYNAX® Active components : nystatin 100 000 IU + neomycin sulphate 35 000 IU + polymyxin B sulphate 35 000 IU Dosage : 1 capsule intravaginally per day (administered at bedtime lying down) 12 vaginal soft capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>miconazole + placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Name : GYNODAKTARIN® Active components : miconazole nitrate 400 mg Dosage : 1 capsule intravaginally per day (administered at bedtime, lying down) 3 vaginal soft capsules followed by 9 placebo vaginal soft capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>POLYGYNAX®</intervention_name>
    <arm_group_label>POLYGYNAX®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GYNODAKTARIN®</intervention_name>
    <arm_group_label>miconazole + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>miconazole + placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with an abnormal vaginal discharge associated with one (or more) functional
             vaginal complaints: vaginal burning and/or vaginal pain and/or vaginal irritation
             clinically evoking an infectious vaginitis:

               -  bacterial vaginitis

               -  non-specific vaginitis (atypical symptoms)

               -  mixed vaginitis (i.e. suprainfected fungal vaginitis) and able to receive an
                  empirical local treatment

        Exclusion Criteria:

          1. Recurrent patient; i.e. a patient who has had at least 4 episodes of infectious
             vaginitis in the 12 months prior to inclusion

          2. Vaginal infection justifying systemic therapy

          3. History of atrophic vaginitis or suspected atrophic vaginitis at inclusion

          4. Patient presenting with signs of genital herpes or signs of non-infectious vulvar
             pathology (vulvodynia, psoriasis, eczema, lichen sclerosus, lichen planus, contact
             dermatitis, candida intertrigo, vulval intraepithelial neoplasia (VIN))

          5. Patient with current Sexually Transmitted Infection (STI) and/or patients with
             clinical suspicion of STI

          6. Disease or concomitant treatment that could cause decreased immunity (i.e. diabetes
             mellitus, corticosteroids treatments)

          7. Systemic anti-infective treatment (antibiotic, antifungal) within two weeks prior to
             inclusion

          8. Patient menstruating or patient with menometrorrhagia due to hormonal imbalance at the
             time of inclusion

          9. Pregnant or lactating women or delivery within last 1 month
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Marc BOHBOT, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Alfred Fournier</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>TURKOVA</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PERCEVAL</name>
      <address>
        <city>Lyon</city>
        <zip>69009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MARICIC</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GATOVA</name>
      <address>
        <city>Martin</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>France</country>
    <country>Serbia</country>
    <country>Slovakia</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>July 29, 2015</study_first_submitted>
  <study_first_submitted_qc>August 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2015</study_first_posted>
  <results_first_submitted>September 21, 2017</results_first_submitted>
  <results_first_submitted_qc>August 13, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 22, 2019</results_first_posted>
  <last_update_submitted>August 13, 2018</last_update_submitted>
  <last_update_submitted_qc>August 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaginitis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>3 patients who signed an Informed Consent Form (ICF) were screen failed and were not randomized in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>POLYGYNAX®</title>
          <description>Name : POLYGYNAX® Active components : nystatin 100 000 IU + neomycin sulphate 35 000 IU + polymyxin B sulphate 35 000 IU Dosage : 1 capsule intravaginally per day (administered at bedtime lying down) 12 vaginal soft capsules
POLYGYNAX®</description>
        </group>
        <group group_id="P2">
          <title>Miconazole + Placebo</title>
          <description>Name : GYNODAKTARIN® Active components : miconazole nitrate 400 mg Dosage : 1 capsule intravaginally per day (administered at bedtime, lying down) 3 vaginal soft capsules followed by 9 placebo vaginal soft capsules
GYNODAKTARIN®
Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="326"/>
                <participants group_id="P2" count="332"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set (FAS)</title>
              <participants_list>
                <participants group_id="P1" count="302"/>
                <participants group_id="P2" count="309"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Per Protocol Set (PPS)</title>
              <participants_list>
                <participants group_id="P1" count="277"/>
                <participants group_id="P2" count="275"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="325"/>
                <participants group_id="P2" count="328"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="270"/>
                <participants group_id="P2" count="261"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="71"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>POLYGYNAX®</title>
          <description>Name : POLYGYNAX® Active components : nystatin 100 000 IU + neomycin sulphate 35 000 IU + polymyxin B sulphate 35 000 IU Dosage : 1 capsule intravaginally per day (administered at bedtime lying down) 12 vaginal soft capsules
POLYGYNAX®</description>
        </group>
        <group group_id="B2">
          <title>Miconazole + Placebo</title>
          <description>Name : GYNODAKTARIN® Active components : miconazole nitrate 400 mg Dosage : 1 capsule intravaginally per day (administered at bedtime, lying down) 3 vaginal soft capsules followed by 9 placebo vaginal soft capsules
GYNODAKTARIN®
Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="302"/>
            <count group_id="B2" value="309"/>
            <count group_id="B3" value="611"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.70" spread="10.13"/>
                    <measurement group_id="B2" value="33.73" spread="10.07"/>
                    <measurement group_id="B3" value="34.21" spread="10.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="302"/>
                    <measurement group_id="B2" value="309"/>
                    <measurement group_id="B3" value="611"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Treatment Efficacy Assessed by the Investigator After Thorough Gynaecological Examination and Patient's Interview at End of Treatment Visit</title>
        <description>Success is defined by resolution (return to patient's usual gynaecological conditions, i.e. before the episode which warranted inclusion in the study) OR substantial improvement of clinical signs of infectious vaginitis (i.e. abnormal vaginal discharge), and/or vaginal symptoms (vaginal burning and/or vaginal pain, and/or vaginal irritation).
Failure is defined by persistence or worsening of symptoms and clinical signs or requirement of an alternative or specific treatment.
Not considered as &quot;Treatment Failure&quot;:
The need to initiate a specific treatment because of a Sexually Transmitted Infection (STI) (trichomoniasis; gonococcal and chlamydial infections) detected from the vaginal sample at Visit 1 / D1.
Patients presenting with only vulvar complaints not considered as related to infectious vaginitis.</description>
        <time_frame>15 days after first treatment administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>POLYGYNAX®</title>
            <description>Name : POLYGYNAX® Active components : nystatin 100 000 IU + neomycin sulphate 35 000 IU + polymyxin B sulphate 35 000 IU Dosage : 1 capsule intravaginally per day (administered at bedtime lying down) 12 vaginal soft capsules
POLYGYNAX®</description>
          </group>
          <group group_id="O2">
            <title>Miconazole + Placebo</title>
            <description>Name : GYNODAKTARIN® Active components : miconazole nitrate 400 mg Dosage : 1 capsule intravaginally per day (administered at bedtime, lying down) 3 vaginal soft capsules followed by 9 placebo vaginal soft capsules
GYNODAKTARIN®
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Treatment Efficacy Assessed by the Investigator After Thorough Gynaecological Examination and Patient's Interview at End of Treatment Visit</title>
          <description>Success is defined by resolution (return to patient's usual gynaecological conditions, i.e. before the episode which warranted inclusion in the study) OR substantial improvement of clinical signs of infectious vaginitis (i.e. abnormal vaginal discharge), and/or vaginal symptoms (vaginal burning and/or vaginal pain, and/or vaginal irritation).
Failure is defined by persistence or worsening of symptoms and clinical signs or requirement of an alternative or specific treatment.
Not considered as &quot;Treatment Failure&quot;:
The need to initiate a specific treatment because of a Sexually Transmitted Infection (STI) (trichomoniasis; gonococcal and chlamydial infections) detected from the vaginal sample at Visit 1 / D1.
Patients presenting with only vulvar complaints not considered as related to infectious vaginitis.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Success</title>
                  <measurement_list>
                    <measurement group_id="O1" value="275"/>
                    <measurement group_id="O2" value="268"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Failure</title>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Vaginal Discharge and in Each Associated Vaginal Clinical Symptoms Reported by the Patient in the Diary</title>
        <description>This outcome was evaluated using a Visual Analogue Scale (VAS) completed by the patient.
The scale measured the level of each vaginal symptom experienced during the day (vaginal discharge, vaginal burning, vaginal pain and vaginal irritation).
Scale ranges = 0 to 100 0=none symptom 100=maximum intensity of symptom Time points used in the calculation= D1 to D14</description>
        <time_frame>during 14 days after first treatment intake</time_frame>
        <group_list>
          <group group_id="O1">
            <title>POLYGYNAX®</title>
            <description>Name : POLYGYNAX® Active components : nystatin 100 000 IU + neomycin sulphate 35 000 IU + polymyxin B sulphate 35 000 IU Dosage : 1 capsule intravaginally per day (administered at bedtime lying down) 12 vaginal soft capsules
POLYGYNAX®</description>
          </group>
          <group group_id="O2">
            <title>Miconazole + Placebo</title>
            <description>Name : GYNODAKTARIN® Active components : miconazole nitrate 400 mg Dosage : 1 capsule intravaginally per day (administered at bedtime, lying down) 3 vaginal soft capsules followed by 9 placebo vaginal soft capsules
GYNODAKTARIN®
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Vaginal Discharge and in Each Associated Vaginal Clinical Symptoms Reported by the Patient in the Diary</title>
          <description>This outcome was evaluated using a Visual Analogue Scale (VAS) completed by the patient.
The scale measured the level of each vaginal symptom experienced during the day (vaginal discharge, vaginal burning, vaginal pain and vaginal irritation).
Scale ranges = 0 to 100 0=none symptom 100=maximum intensity of symptom Time points used in the calculation= D1 to D14</description>
          <units>mm</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Vaginal discharge absolute change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.43" lower_limit="29.94" upper_limit="32.91"/>
                    <measurement group_id="O2" value="29.54" lower_limit="28.07" upper_limit="31.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaginal burning absolute change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.89" lower_limit="26.66" upper_limit="29.12"/>
                    <measurement group_id="O2" value="27.03" lower_limit="25.81" upper_limit="28.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaginal pain absolute change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.93" lower_limit="15.86" upper_limit="18.01"/>
                    <measurement group_id="O2" value="17.17" lower_limit="16.10" upper_limit="18.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaginal irritation absolute change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.37" lower_limit="28.06" upper_limit="30.67"/>
                    <measurement group_id="O2" value="28.79" lower_limit="27.51" upper_limit="30.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaginal combined clinical symptoms score absolute</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.96" lower_limit="26.79" upper_limit="31.14"/>
                    <measurement group_id="O2" value="28.20" lower_limit="26.04" upper_limit="30.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Change in Vaginal Discharge Assessed by the Investigator</title>
        <description>The vaginal discharge is assessed by the investigator by using a score:
0=absent
mild: insufficient for speculum collection
moderate: sufficient for speculum collection
abundant: visible at the introitus even before speculum introduction.</description>
        <time_frame>15 days after first treatment administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>POLYGYNAX®</title>
            <description>Name : POLYGYNAX® Active components : nystatin 100 000 IU + neomycin sulphate 35 000 IU + polymyxin B sulphate 35 000 IU Dosage : 1 capsule intravaginally per day (administered at bedtime lying down) 12 vaginal soft capsules
POLYGYNAX®</description>
          </group>
          <group group_id="O2">
            <title>Miconazole + Placebo</title>
            <description>Name : GYNODAKTARIN® Active components : miconazole nitrate 400 mg Dosage : 1 capsule intravaginally per day (administered at bedtime, lying down) 3 vaginal soft capsules followed by 9 placebo vaginal soft capsules
GYNODAKTARIN®
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Change in Vaginal Discharge Assessed by the Investigator</title>
          <description>The vaginal discharge is assessed by the investigator by using a score:
0=absent
mild: insufficient for speculum collection
moderate: sufficient for speculum collection
abundant: visible at the introitus even before speculum introduction.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="300"/>
                <count group_id="O2" value="307"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Leucorrhoea score change - Deterioration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leucorrhoea score change - No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leucorrhoea score change - Improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="280"/>
                    <measurement group_id="O2" value="276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Treatment Efficacy (Success/Failure) Assessed by the Investigator After Thorough Gynaecological Examination and Patient's Interview at End of Study Visit</title>
        <description>Success and Failure (same definition as the primary outcome measure)</description>
        <time_frame>22 days after first treatment administration</time_frame>
        <population>There were 5 and 6 missing values respectively in Polygynax and Miconazole + placebo arms.</population>
        <group_list>
          <group group_id="O1">
            <title>POLYGYNAX®</title>
            <description>Name : POLYGYNAX® Active components : nystatin 100 000 IU + neomycin sulphate 35 000 IU + polymyxin B sulphate 35 000 IU Dosage : 1 capsule intravaginally per day (administered at bedtime lying down) 12 vaginal soft capsules
POLYGYNAX®</description>
          </group>
          <group group_id="O2">
            <title>Miconazole + Placebo</title>
            <description>Name : GYNODAKTARIN® Active components : miconazole nitrate 400 mg Dosage : 1 capsule intravaginally per day (administered at bedtime, lying down) 3 vaginal soft capsules followed by 9 placebo vaginal soft capsules
GYNODAKTARIN®
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Treatment Efficacy (Success/Failure) Assessed by the Investigator After Thorough Gynaecological Examination and Patient's Interview at End of Study Visit</title>
          <description>Success and Failure (same definition as the primary outcome measure)</description>
          <population>There were 5 and 6 missing values respectively in Polygynax and Miconazole + placebo arms.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Success</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="297"/>
                    <count group_id="O2" value="303"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="252"/>
                    <measurement group_id="O2" value="250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="297"/>
                    <count group_id="O2" value="303"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Investigator's Global Satisfaction</title>
        <description>The investigator filled the satisfaction questionnaire during the end of treatment visit.
Six ratings are available: Very Bad, Bad, Somewhat Bad, Somewhat Good, Good and Very Good.</description>
        <time_frame>15 days after first administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>POLYGYNAX®</title>
            <description>Name : POLYGYNAX® Active components : nystatin 100 000 IU + neomycin sulphate 35 000 IU + polymyxin B sulphate 35 000 IU Dosage : 1 capsule intravaginally per day (administered at bedtime lying down) 12 vaginal soft capsules
POLYGYNAX®</description>
          </group>
          <group group_id="O2">
            <title>Miconazole + Placebo</title>
            <description>Name : GYNODAKTARIN® Active components : miconazole nitrate 400 mg Dosage : 1 capsule intravaginally per day (administered at bedtime, lying down) 3 vaginal soft capsules followed by 9 placebo vaginal soft capsules
GYNODAKTARIN®
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Investigator's Global Satisfaction</title>
          <description>The investigator filled the satisfaction questionnaire during the end of treatment visit.
Six ratings are available: Very Bad, Bad, Somewhat Bad, Somewhat Good, Good and Very Good.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="300"/>
                <count group_id="O2" value="307"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Very good - Good</title>
                  <measurement_list>
                    <measurement group_id="O1" value="265"/>
                    <measurement group_id="O2" value="252"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Somewhat good - Somewhat bad</title>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Bad - Very bad</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient's Global Satisfaction</title>
        <description>The patient filled the satisfaction questionnaire on her patient's diary at home the eve of the End of Treatment Visit.
Six ratings are available: Very Bad, Bad, Somewhat Bad, Somewhat Good, Good and Very Good.</description>
        <time_frame>15 days after first administration</time_frame>
        <population>There were 10 and 11 missing values respectively in Polygynax and Miconazole + placebo arms.</population>
        <group_list>
          <group group_id="O1">
            <title>POLYGYNAX®</title>
            <description>Name : POLYGYNAX® Active components : nystatin 100 000 IU + neomycin sulphate 35 000 IU + polymyxin B sulphate 35 000 IU Dosage : 1 capsule intravaginally per day (administered at bedtime lying down) 12 vaginal soft capsules
POLYGYNAX®</description>
          </group>
          <group group_id="O2">
            <title>Miconazole + Placebo</title>
            <description>Name : GYNODAKTARIN® Active components : miconazole nitrate 400 mg Dosage : 1 capsule intravaginally per day (administered at bedtime, lying down) 3 vaginal soft capsules followed by 9 placebo vaginal soft capsules
GYNODAKTARIN®
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Patient's Global Satisfaction</title>
          <description>The patient filled the satisfaction questionnaire on her patient's diary at home the eve of the End of Treatment Visit.
Six ratings are available: Very Bad, Bad, Somewhat Bad, Somewhat Good, Good and Very Good.</description>
          <population>There were 10 and 11 missing values respectively in Polygynax and Miconazole + placebo arms.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="292"/>
                <count group_id="O2" value="298"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Very good - Good</title>
                  <measurement_list>
                    <measurement group_id="O1" value="239"/>
                    <measurement group_id="O2" value="233"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Somewhat good - Somewhat bad</title>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Bad - Very bad</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>22 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>POLYGYNAX®</title>
          <description>Name : POLYGYNAX® Active components : nystatin 100 000 IU + neomycin sulphate 35 000 IU + polymyxin B sulphate 35 000 IU Dosage : 1 capsule intravaginally per day (administered at bedtime lying down) 12 vaginal soft capsules
POLYGYNAX®</description>
        </group>
        <group group_id="E2">
          <title>Miconazole + Placebo</title>
          <description>Name : GYNODAKTARIN® Active components : miconazole nitrate 400 mg Dosage : 1 capsule intravaginally per day (administered at bedtime, lying down) 3 vaginal soft capsules followed by 9 placebo vaginal soft capsules
GYNODAKTARIN®
Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Patient pregnant exposed to study medications</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="328"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Medical Affairs</name_or_title>
      <organization>Laboratoire Innotech International</organization>
      <phone>+33 (0)1 46 15 29 00</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

